Tirzepatide
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
Eli Lilly · Phase 2 · Recruiting · Enrollment 372
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1005 injection dose group 1 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose group 2 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose group 3 | n/r | n/r | n/r | n/r |
| tirzepatide injection | n/r | n/r | n/r | n/r |
Not shown
- HDM1005 injection dose group 1: endpoint not reported
- HDM1005 injection dose group 2: endpoint not reported
- HDM1005 injection dose group 3: endpoint not reported
- tirzepatide injection: endpoint not reported